Skip to main content
Homepage of ProQR
  • We are ProQR
    • About ProQR Therapeutics
    • Founding story
    • Leadership
    • Careers
      • Vacancies
    • Contact
    • Events
  • Science & Pipeline
    • Sepofarsen (CEP290 LCA10)
    • Ultevursen (USH2A RP)
    • Axiomer technology
      • How Axiomer works
    • RNA therapy
    • Partnerships
    • Presentations & Publications
  • Patients & Community
    • Blogs, Stories & News
    • What is a clinical trial?
      • Illuminate Ph2/3 trial (CEP290 LCA10)
      • Brighten pediatric trial (CEP290 LCA10)
      • Sirius Ph2/3 trial (USH2A RP)
    • Inherited retinal diseases
      • Leber congenital amaurosis
      • Retinitis pigmentosa
      • Usher syndrome
    • The importance of genetic testing
      • My Retina Tracker program
    • Eye Connect newsletter
    • Expanded access policy
  • Health Professionals
    • Clinical research
    • Events
    • Expert Eyes newsletter
    • Expert Perspectives series
    • HCP resources
      • IRDs and assessment
      • Patient journey and referral
      • Genetic testing
      • Intravitreal injection
  • News
    • Press Releases
    • Blogs, stories and news
  • Investors & Media
    • Events
    • Email alerts
    • Corporate presentation
    • Share performance
    • Financial information
    • Corporate governance
    • Analysts
  1. Home
  2. Investors & Media
Listen

Email alerts

Share

  • Facebook
  • Linkedin
  • Twitter
  • Whatsapp
  • Email

Subscribe for email alerts

Get an email alert every time ProQR issues a press release. Never miss a quarterly report, event announcement, or news update again.

Share page

  • Facebook
  • Linkedin
  • Twitter
  • Whatsapp
  • Email

Follow us

  • Twitter (opens in new window)
  • Facebook (opens in new window)
  • Instagram (opens in new window)
  • Linkedin (opens in new window)
  • Youtube (opens in new window)
  • Soundcloud (opens in new window)
  • Contact
  • Disclaimer
  • Privacy
  • Sitemap

© 2022 ProQR Therapeutics. All Rights Reserved.

Back to top